Sex differences in the pharmacokinetics of pioglitazone in rats

Clinical studies have suggested that pioglitazone, an insulin sensitizer, has a stronger effect in women than in men. To determine the sex difference in the pharmacokinetics of pioglitazone, we examined the plasma and white adipose tissue levels of pioglitazone and its active metabolites (M-II, M-II...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Comparative biochemistry and physiology. Toxicology & pharmacology 2003-09, Vol.136 (1), p.85-94
Hauptverfasser:	Fujita, Yukiyoshi, Yamada, Yasuhiko, Kusama, Makiko, Yamauchi, Toshimasa, Kamon, Junji, Kadowaki, Takashi, Iga, Tatsuji
Format:	Artikel
Sprache:	eng
Schlagworte:	Active metabolites Adipose tissue Adipose Tissue - drug effects Adipose Tissue - metabolism Administration, Oral Animals Area Under Curve Concentration Female Hypoglycemic Agents - administration & dosage Hypoglycemic Agents - pharmacokinetics Male Models, Biological Peroxisome proliferator-activated receptor γ (PPARγ) Pharmacokinetics Pioglitazone Rats Rats, Wistar Sex difference Sex Factors Thiazolidinediones - administration & dosage Thiazolidinediones - pharmacokinetics
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Clinical studies have suggested that pioglitazone, an insulin sensitizer, has a stronger effect in women than in men. To determine the sex difference in the pharmacokinetics of pioglitazone, we examined the plasma and white adipose tissue levels of pioglitazone and its active metabolites (M-II, M-III and M-IV) in male and female rats treated with a single or repeated oral administration of pioglitazone (10 mg/kg). The AUCs of pioglitazone (149.6±22.6 vs. 103.3±14.0 μg·h/ml; P
ISSN:	1532-0456 1878-1659
DOI:	10.1016/S1532-0456(03)00194-7